◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksS › SBX

SynBiotic SE (SBX) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-29

SynBiotic SE (SBX) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Düsseldorf, Germany with about 79 employees. Its market capitalization is roughly €5 million. In the fiscal year ended 2024-12-31, SBX reported €14M in revenue and (€10M) in net income.

SynBiotic SE, together with its subsidiaries, engages in the pharmaceutical business in Germany and Europe. It is involved in the cultivation, research, development, production, and distribution of medicinal cannabis; industrial hemp; and cannabidiol and cannabinoid-based products.

Interactive charts & full statements →

SBX Revenue & Earnings History — Annual Income Statement

Income statement2024-12-312023-12-312022-12-312021-12-31
Total Revenue€14M€4M€8M€9M
Gross Profit€5M€2M€4M€5M
Operating Income (EBIT)(€10M)(€11M)(€25M)(€11M)
Net Income(€10M)(€11M)(€24M)(€13M)

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SBX Free Cash Flow History

SBX Balance Sheet History

Balance sheet2024-12-312023-12-312022-12-312021-12-31
Total Assets€46M€35M€41M€61M
Total Liabilities€25M€20M€18M€24M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SBX viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

← SBUYAll “S” companiesSBXD →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.